initial public offerings (IPOs) trading on American exchanges

Wednesday, August 23, 2017

Sienna Biopharmaceuticals (SNNA) started trading on the Nasdaq on 27 July 2017

Sienna Biopharmaceuticals, Inc. is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125. The Company has developed over 70 products. Its SNA-120 and SNA-125 are generated through its Topical by Design platform technology. Its SNA-120 is a Topical Tropomyosin Receptor Kinase A (TrkA) inhibitor for pruritus and psoriasis. Its SNA-125 is a Topical TrkA/Janus Kinase 3 (JAK3) Inhibitor for atopic dermatitis, psoriasis and pruritus. Its SNA-001 is a Topical Photoparticle Therapy for medical and aesthetic applications. Its SNA-001 Topical Photoparticle Therapy is used for localized and non-systemic treatment of acne. Its SNA-001 Topical Photoparticle Therapy is used for reduction of light-pigmented hair.


30699 Russell Ranch Rd Ste 140
United States

No comments:

Post a Comment